Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer

20 Mar 2013

Abstract excerpt

BACKGROUND: The excision repair cross-complementation group 1 (ERCC1) protein is a potential prognostic biomarker of the efficacy of cisplatin-based chemotherapy in non-small-cell lung cancer (NSCLC). Although several ongoing trials are evaluating the level of expression of ERCC1, no consensus has been reached regarding a method for evaluation. METHODS: We used the 8F1 antibody to measure the level of expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to DNA Repair Mechanisms
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23514287
DOI: 10.1056/nejmoa1214271

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung CancerPMID 23514287Read ↗

Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.Semantic proximity Read ↗

Nucleotide Excision Repair Pathways Involved in Cisplatin Resistance in Non-Small-Cell Lung CancerSemantic proximity Read ↗

ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.Semantic proximity Read ↗

Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer.Semantic proximity Read ↗

Lack of correlation between ERCC1 (C8092A) single nucleotide polymorphism and efficacy/toxicity of platinum based chemotherapy in Chinese patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.Semantic proximity Read ↗

Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.Semantic proximity Read ↗

Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapySemantic proximity Read ↗

Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma.Semantic proximity Read ↗

Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathologySemantic proximity Read ↗

Pharmacogenetics of platinum-based chemotherapy in non-small cell lung cancer: predictive validity of polymorphisms of ERCC1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.